Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Silver_Bullet who wrote (9724)	11/27/2002 6:39:12 PM
From: KonKilo	Respond to of 48461

ROHN has some potentially chilling news: Dow Jones Business News ROHN Announces Further Development In Probe Wednesday November 27, 6:12 pm ET PEORIA, Ill. -(Dow Jones)- Rohn Industries Inc. (NasdaqSC:ROHN - News) said new issues have arisen out of the company's testing and repair program for its internal flange poles. ADVERTISEMENTDuring the second quarter, Rohn learned an internal flange pole sold to one of its customers had collapsed. Internal flange poles are connecting devices between sections of a support device. As a result, the company advised the U.S. Consumer Product Safety Commission and implemented a testing program to help ensure that internal flange poles it sold since 1999 conform to quality standards. In a press release Wednesday, Rohn said one of its customers began its own testing and repair program of the internal flange poles it purchased from the company, and recently notified Rohn that it expects reimbursement for any losses and expenses it incurs in testing and repairing any problems. Although the company's potential exposure to its customers cannot be estimated at this time, the amount is likely to be material, Rohn said. Through Sept. 30, the company had incurred total costs of about $3.7 million in connection with the testing and repair program it implemented for its internal flange poles. Last month, Rohn was contacted by an employee of an independent testing organization hired by Rohn to assist in the internal flange pole testing program. The employee alleged certain problems with that organization's test results that called into question the integrity of those results. Rohn said its own investigation of the individual's allegations confirmed certain problems with that organization's test results. Rohn said it is still in the process of evaluating the full nature and extent of the problems. biz.yahoo.com

To: Silver_Bullet who wrote (9724)	11/27/2002 9:39:28 PM
From: tsigprofit	Read Replies (1) \| Respond to of 48461

ASTM - thanks FT. You just never know with these rats... I noticed that STEM had been outperforming ASTM month after month, but then in October and November, this changed. Probably safest to have both. Take care, Matt

To: Silver_Bullet who wrote (9724)	12/1/2002 11:28:22 AM
From: tsigprofit	Respond to of 48461

ASTM - DARPA info.. Just an update on ASTM. I had posted about DoD funding, but I looked back for the link after I got a private email, and see it is actually DARPA - which is the research arm of defense... Here's an excerpt from September: Aastrom Biosciences Receives $0.9 Million Grant From DARPA for Immune System Research WEDNESDAY, SEPTEMBER 18, 2002 8:02 AM - PR Newswire ANN ARBOR, Mich., Sep 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- Aastrom Biosciences, Inc. (ASTM) announced that it was awarded approximately $897,000 of a collaborative grant by the Defense Advanced Research Projects Agency (DARPA) providing funding over an 18 month period for the research and development of a system to engineer human stem cells into an artificial immune system. In addition to Aastrom, the multi-disciplinary team working on this project includes researchers from Florida State University and Tulane University, and is being led by scientists at the Ohio State University Research Foundation. A total grant of approximately $3.7 million was awarded to support the efforts of the collaborative scientific and engineering team involved in this research project, subject to appropriate progress as determined by DARPA. DARPA structured this Engineered Tissue Constructs program into two phases. The current grant supports Phase I, intended to establish the reliable differentiation of human stem cells into multiple immune functions within a 3-D culture system. Under a separate request, Phase II of the program will focus on the continuation of Phase I technologies. I'm following William's lead here, and figure defense money is a vote of confidence in the company right now. Also - I'm looking to hold both STEM and ASTM for the long-term - 3-5 years or more - of course I will sell if we see big spikes, and buy on dips - regular rat stuff. I figure one of these two will survive, and I want to be in this area going forward. A few more days like last week on ASTM would be great, right? Matt